Key clinical point: In a small sample of female sexual partners of patients on teriflunomide, 4 out of 10 had low detectable levels of the drug.
Major finding: Four women had detectable teriflunomide levels that averaged 0.045 mcg/mL (ranging from 0.022 to 0.077 mcg/mL).
Study details: An analysis of 10 couples that compared serum levels of teriflunomide in men with relapsing multiple sclerosis with those of their female partners.
Disclosures: The study was supported by a investigator-sponsored research grant from Sanofi-Genzyme. Dr. Guarnaccia reported that he has received speaking honoraria and educational grants from Sanofi-Genzyme, Biogen, Teva, Acorda Therapeutics, Bayer, EMD Serono, and Genentech.
Guarnaccia JB et al. ACTRIMS Forum 2019, Poster 115.